It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements.

The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they risk suspension (and consequential panic and anger from shareholders).

Here’s some of the reports which have caught our eye today.



Fintech MONEYME grew its revenue in FY22 to around $138m, with 4Q22 revenue >$55m. Gross customer receivables for FY22 also increased to $1.4 billion up 366% on pcp.

The Q4 gross revenue of $55m was up 190% vs pcp, and was much higher than the $35m achieved in Q3.

Contracted revenue for the quarter was $398m, up 306% on pcp,  while loan originations were $334m (49% of which made up of secured asset finance), up 107% on pcp.

MONEYME’s closing average Equifax Score increased to 704 vs 650 in the same period last year.

Net losses on the books decreased to 3%, compared to 5% in Q4 of FY21.

With strong unit economics and scale advantages delivered, MONEYME said its near term shift in focus from high to more moderated growth will drive an earlier realisation of cash returns.

The company now expects to deliver in excess of $200m in revenue for FY23.

Clayton Howes, MONEYME’s CEO said:

“MONEYME’s agility during evolving market conditions is part of what makes MONEYME a strong consumer lender.

“Our innovation-led business model gives us the edge to recalibrate quickly to support the ongoing delivery of profitable returns.”


Prescient Therapeutics (ASX:PTX)

The clinical-stage oncology company reported strong cash balance of $12.27 million for the June quarter, supporting its multiple cancer programs.

Costs for the quarter included ongoing clinical trials and manufacturing for PTX-100 and PTX-200, developing the OmniCAR platform, as well as the newly unveiled high-performance cell therapy manufacturing technology.

Although no results have been made public on the OmniCAR programs, the company says that steady progress has been made across its programs, including in-vivo studies.

Total cash outflows for the quarter were largely in line with the previous quarter at $1.2 million, with $0.5 million invested in R&D activities in Australia and the US.

The PTX-200 study has now expanded its cohort after a fourth complete remission.

Combined with chemotherapy (cytarabine) in patients with relapsed and refractory acute myeloid leukemia (AML), the  study of PTX-200 reported that another patient had a complete remission of their disease at the 45mg/m2 dose.

In parallel, the PTX-100 has also expanded its study on T-cell lymphoma patients.

Patients with T-cell lymphomas (TCL) are being steadily enrolled and treated in the expansion cohort under the leadership of Professor Miles Prince.

Prescient anticipates that recruitment remains on track for completion by the end of calendar 2022.


Spectur (ASX:SP3)

The developer of security, surveillance and warning solutions has delivered FY22 revenue of $5.83m (up 11% on pcp), of which $3.33m (57%) is classified as recurring revenue.

For Q4, Spectur delivered steady revenue of $1.43m, including $491k in the month of June.

Recurring revenue for the year (comprising subscriptions and rentals) grew to $3.33m, with June annualised recurring revenue equivalent to a yearly run rate of $3.76m.

Total available funding at end of June 2022 was $1.43m, with net cash used in operating activities in Q4 FY22 of $248k.
The company’s unweighted sales pipeline grew to $10.2m  (weighted $3.55m), underpinning expectations of continuing growth into FY23.

During the quarter, Spectur successful placement of $1.86m in July, and a Securities Purchase Plan (SPP) to raise $500k is now open to shareholders.

“We have a clear strategic path and, with recent funding activities, the balance sheet to execute,” said Spectur CEO, Gerard Dyson.

“It is our expectation that the work we will be doing to build the sales and marketing resources, globalise our technology and plan for further expansion internationally will drive the inflection point in sales, revenue and ultimately profitability and cash generation.”


Spacetalk (ASX:SPA)

Spacetalk achieved total revenue of $4.1 million, a 40.9% increase on pcp. 

Total revenue for 2022 financial year was $20.7 million, a 37.1% increase on pcp. This the first time the company’s annual revenues exceeded $20 million. 

Wearables revenue for the three months to end June 2022 was $3.5 million, a 51.5% increase on the prior corresponding quarter. 

4QFY22 Annualised Recurring Revenue (ARR) from Spacetalk App monthly subscriptions was $3.8 million, up 40.7% compared to pcp. 

Wearables sales for the quarter were achieved with marketing expenses of $0.5 million compared to $0.3 million in the pcp. 

Revenue for the MGM Schools Business for the three months to 30 June 2022 was $0.6 million, a 4.9% increase on the pcp. 

The MGM Schools Business continues to be a strong net cashflow contributor for the company. 


Share prices today:


At Stockhead we tell it like it is. While MONEYME, Spectur and Prescient are Stockhead advertisers, they did not sponsor this article.